Maximising clinical benefit with adequate patient management beyond the second line in mCRC

Argiles, G; Arnold, D; Prager, G; Sobrero, AF; Van Cutsem, E

Argiles, G (reprint author), Hosp Valle De Hebron, Med Oncol, Barcelona, Spain.

ESMO OPEN, 2019; 4 (2):

Abstract

New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the opti......

Full Text Link